Association between RUNX3 promoter methylation and non-small cell lung cancer: a meta-analysis

由 Liang, Yali, He, Lianping, Yuan, Hui, Jin, Yuelong, Yao, Yingshui
出版 2014

Absolute Oral Bioavailability of Glasdegib (PF‐04449913), a Smoothened Inhibitor, in Randomized Healthy Volunteers

由 Shaik, Naveed, Hee, Brian, Liang, Yali, LaBadie, Robert Roland
發表在 Clin Pharmacol Drug Dev (2019)

Gait Characteristics of Children with Spastic Cerebral Palsy during Inclined Treadmill Walking under a Virtual Reality Environment

由 Ma, Ye, Liang, Yali, Kang, Xiaodong, Shao, Ming, Siemelink, Lilja, Zhang, Yanxin
發表在 Appl Bionics Biomech (2019)

MAP65-1a positively regulates H(2)O(2) amplification and enhances brassinosteroid-induced antioxidant defence in maize

由 Zhu, Yuan, Zuo, Mingxing, Liang, Yali, Jiang, Mingyi, Zhang, Jianhua, Scheller, Henrik Vibe, Tan, Mingpu, Zhang, Aying
出版 2013

Pharmacokinetic Properties of Single and Multiple Doses of Ertugliflozin, a Selective Inhibitor of SGLT2, in Healthy Chinese Subjects

由 Li, Yinhua, Mu, Yuting, Shi, Haihong, Liang, Yali, Liu, Zeyuan, Matschke, Kyle, Hickman, Anne, Krishna, Rajesh, Sahasrabudhe, Vaishali
發表在 Clin Pharmacol Drug Dev (2019)

Pharmacokinetics and pharmacodynamics of PF-05231023, a novel long-acting FGF21 mimetic, in a first-in-human study

由 Dong, Jennifer Q, Rossulek, Michelle, Somayaji, Veena R, Baltrukonis, Daniel, Liang, Yali, Hudson, Krischan, Hernandez-Illas, Martha, Calle, Roberto A
發表在 Br J Clin Pharmacol (2015)

A PK/PD study comparing twice-daily to once-daily dosing regimens of ertugliflozin in healthy subjects

由 Dawra, Vikas Kumar, Liang, Yali, Shi, Haihong, Bass, Almasa, Hickman, Anne, Terra, Steven G., Zhou, Susan, Cutler, David, Sahasrabudhe, Vaishali
發表在 Int J Clin Pharmacol Ther (2019)

End‐to‐end application of model‐informed drug development for ertugliflozin, a novel sodium‐glucose cotransporter 2 inhibitor

由 Fediuk, Daryl J., Nucci, Gianluca, Dawra, Vikas K., Callegari, Ernesto, Zhou, Susan, Musante, Cynthia J., Liang, Yali, Sweeney, Kevin, Sahasrabudhe, Vaishali
發表在 CPT Pharmacometrics Syst Pharmacol (2021)

Bioequivalence and Bioavailability of an Orodispersible Tablet of Sildenafil Citrate in Healthy Chinese Male Subjects

由 Lv, Yuan, Luo, Bin‐yu, LaBadie, Robert R., Zhu, Hua, Feng, Yan, Ernst, Cynthia, Crownover, Penelope H., Liang, Yali, Zhao, Qinying
發表在 Clin Pharmacol Drug Dev (2020)

Meconium microbiome associates with the development of neonatal jaundice

由 Dong, Tianyu, Chen, Ting, White, Richard Allen, Wang, Xu, Hu, Weiyue, Liang, Yali, Zhang, Yuqing, Lu, Chuncheng, Chen, Minjian, Aase, Heidi, Xia, Yankai
發表在 Clin Transl Gastroenterol (2018)

Systematic Analysis of Impact of Sampling Regions and Storage Methods on Fecal Gut Microbiome and Metabolome Profiles

由 Liang, Yali, Dong, Tianyu, Chen, Minjian, He, Lianping, Wang, Tingzhang, Liu, Xingyin, Chang, Hang, Mao, Jian-Hua, Hang, Bo, Snijders, Antoine M., Xia, Yankai
發表在 mSphere (2020)

Bioequivalence of Ertugliflozin/Metformin Fixed‐Dose Combination Tablets and Coadministration of Respective Strengths of Individual Components

由 Dawra, Vikas Kumar, Liang, Yali, Wei, Hua, Pelletier, Kathleen, Shi, Haihong, Hickman, Anne, Bass, Almasa, Terra, Steven G., Zhou, Susan, Krishna, Rajesh, Sahasrabudhe, Vaishali
發表在 Clin Pharmacol Drug Dev (2019)

Assessment of the Drug Interaction Potential of Ertugliflozin With Sitagliptin, Metformin, Glimepiride, or Simvastatin in Healthy Subjects

由 Dawra, Vikas Kumar, Cutler, David L., Zhou, Susan, Krishna, Rajesh, Shi, Haihong, Liang, Yali, Alvey, Christine, Hickman, Anne, Saur, Didier, Terra, Steven G., Sahasrabudhe, Vaishali
發表在 Clin Pharmacol Drug Dev (2018)

Effect of Food on the Pharmacokinetics of Ertugliflozin and Its Fixed‐Dose Combinations Ertugliflozin/Sitagliptin and Ertugliflozin/Metformin

由 Sahasrabudhe, Vaishali, Fediuk, Daryl J., Matschke, Kyle, Shi, Haihong, Liang, Yali, Hickman, Anne, Bass, Almasa, Terra, Steven G., Zhou, Susan, Krishna, Rajesh, Dawra, Vikas K.
發表在 Clin Pharmacol Drug Dev (2018)

Bioequivalence of Ertugliflozin/Sitagliptin Fixed‐Dose Combination Tablets and Coadministration of Respective Strengths of Individual Components

由 Fediuk, Daryl J., Matschke, Kyle, Liang, Yali, Pelletier, Kathleen B., Wei, Hua, Shi, Haihong, Bass, Almasa, Hickman, Anne, Terra, Steven G., Zhou, Susan, Krishna, Rajesh, Sahasrabudhe, Vaishali
發表在 Clin Pharmacol Drug Dev (2019)